Search results for "MAb"

showing 10 items of 1716 documents

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

2018

Abstract Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). Methods LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value. Results A total of 1631 patients who received 12 months of trastuzumab from PH…

Adultmedicine.medical_specialtySide effectReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabInternal medicinemedicineHumansIn patientcardiovascular diseasesCardiotoxicityEjection fractionbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseCardiotoxicityStandard errorChemotherapy AdjuvantEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologySurgeryFemalebusinessAdjuvantcirculatory and respiratory physiologymedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct

A European survey of management approaches in chronic urticaria in children: EAACI Paediatric Urticaria Taskforce

2021

Background: Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0-18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for paediatric urticaria are implemented. Methods: The EAACI Taskforce for paediatric CU disseminated an online clinical survey among EAACI paediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centres. Results: The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly paediatric allergist…

Adultmedicine.medical_specialtyUrticariaImmunologyDermatologyOmalizumabOmalizumaburticaria diagnosischronic urticariaSecond lineSurveys and QuestionnairesHumansImmunology and AllergyMedicineChronic UrticariaChildChronic urticariachildurticaria treatmentbusiness.industryTask forceGuidelineThird lineFamily medicineChronic DiseasePediatrics Perinatology and Child HealthHistamine H1 AntagonistsomalizumabAllergistsApproaches of managementbusinessmedicine.drug
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Pitfall prayer marks: Recognition and appropriate treatment: A case report and review of literature.

2019

Prayer marks are asymptomatic callosities resulting from repeated, extended pressure, and friction exerted on bony prominences when praying on hard ground. A 41-year-old woman with ulcerative colitis treated with infliximab was referred to our clinic due to skin changes on her feet that were suspected to be drug eruptions. The patient presented several asymptomatic, hyperpigmented, and hyperkeratotic plaques over the lateral malleoli suggesting that the lesions had a mechanical cause. Further exploration revealed that the patient, a practicing Muslim, prays in a sitting position called "Julus" several times a day. After color marking, the lesions over the lateral feet left a precise imprint…

Adultmedicine.medical_specialtymedia_common.quotation_subjectDermatologyIslam030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineHyperpigmentationMedicineHumansmedia_commonSkinCallositybusiness.industryFootGeneral surgeryGeneral MedicinehumanitiesPrayerInfliximab030220 oncology & carcinogenesisColitis UlcerativeFemaleHyperkeratotic plaquesDrug EruptionsbusinessSkin lesionDermatologic therapyREFERENCES
researchProduct

Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze.

2006

Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma

Adverse eventCrohn diseaseTuberculosisInfliximab
researchProduct

Interruption of CD28-mediated costimulation during allergen challenge protects mice from allergic airway disease

2012

Background Allergic asthma is a T H 2-promoted hyperreactivity with an immediate, IgE, and mast cell–dependent response followed by eosinophil-dominated inflammation and airway obstruction. Objective Because costimulation by CD28 is essential for T H 2 but not T H 1 responses, we investigated the effect of selective interference with this pathway in mice using the models of ovalbumin and house dust mite–induced airway inflammation. Methods To study the role of CD28 in the effector phase of allergic airway inflammation, we developed an inducibly CD28-deleting mouse strain or alternatively used a CD28 ligand-binding site–specific mouse anti-mouse mAb blocking CD28 engagement. Results We show …

Allergic asthmaLymphocyte ActivationImmunoglobulin Emedicine.disease_causeT-Lymphocytes RegulatoryMice0302 clinical medicineAirway resistanceAllergenImmunology and AllergySensitizationMice Inbred BALB C0303 health sciencesbiologyAntibodies Monoclonalovalbuminrespiratory system3. Good healthmedicine.anatomical_structurecostimulationconditional CD28 knockout miceFemalemedicine.symptomImmunologyInflammation03 medical and health sciencesTh2 CellsCD28 AntigensRespiratory HypersensitivitymedicineAnimalsHumansAntigens DermatophagoidesLymphocyte CountAntibodies Blocking030304 developmental biologyHouse dust miteCD28-specific mAbbusiness.industryReceptor Cross-TalkAirway obstructionmedicine.diseasebiology.organism_classificationMice Mutant Strainsrespiratory tract diseasesDisease Models AnimalCTLA-4Immunologybiology.proteinbusiness030215 immunology
researchProduct

dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies

2017

[EN] Asthma is an airway disease characterised by chronic inflammation with intermittent or permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which vary in terms of their occurrence, frequency, and intensity. The most common associated feature in the airways of patients with asthma is airway inflammation. In recent decades, efforts have been made to characterise the heterogeneous clinical nature of asthma. The interest in improving the definitions of asthma phenotypes and endotypes is growing, although these classifications do not always correlate with prognosis nor are always appropriate therapeutic approaches. Attempts have been made to identify the m…

AllergyDiseaseOmalizumabReviewOmalizumabImmunoglobulin Eimmunomodulation0302 clinical medicine030212 general & internal medicineanti-IgEAnti-Asthmatic Agentsbiological treatmentSpectroscopyBiología molecularbiologyAntibodies MonoclonalAllergic asthmaGeneral MedicineComputer Science Applicationsmedicine.symptommedicine.drugBioquímicaimmunological mechanismsmedicine.drug_classInflammationMonoclonal antibodyCatalysisInorganic Chemistry03 medical and health sciencesmedicineImmunologic FactorsAnimalsHumansfactores inmunitariosPhysical and Theoretical ChemistryMolecular BiologyAsthmaimmunoglobulin E (IgE)Inflammationbusiness.industryOrganic ChemistrybiomarkersMicrobiología médicaasthmaImmunoglobulin Emedicine.diseaseallergyrespiratory tract diseases030228 respiratory systemImmunologybiology.proteinbusiness
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Architecture of a digital PFM controller for IC implementation

2006

This paper presents a digital controller architecture oriented to IC implementation. The classical digital pulse width modulator (D-PWM), using digital analog converter (DAC), is replaced with a Sigma-Delta (/spl Sigma//spl Delta/) modulator based on pulse frequency modulator (PFM) technique. Results of an investigation from a prototype for DC-DC converter, in terms of simulated and experimental performances, are reported, together with harmonic frequency investigation. The control function design is implemented on a field programmable gate array (FPGA). As a consequence of good agreement between simulated and experimental results, the proposed architecture realizes a digital control loop w…

Analog controlEngineeringPulse-frequency modulationbusiness.industryDC-DC convertersLoop (topology)digital controllerComputer Science::Hardware ArchitectureControl theoryElectronic engineeringDigital controlArchitecturebusinessField-programmable gate arrayDigital control systemsPulse-width modulation
researchProduct